Abstract
HbSC disease is the second most common type of sickle cell disease (SCD) in populations of African origin. Although it is often grouped together with other types of SCD, particularly sickle cell anemia (HbSS), it has unique pathophysiology and a different spectrum of laboratory and clinical features. Compared to HbSS, hemoglobin levels are higher, HbF is lower at less than 5%, and most vaso‐occlusive and vasculopathic complications are less frequent, although retinopathy is more common. Despite these differences, there have been no specific guidelines on the management of HbSC disease. This clinical practice guideline was developed by the European Hematology Association (EHA) in accordance with the EHA Guidelines Methodology Framework to provide consensus‐based guidance for the management of children and adults with HbSC disease. A multidisciplinary Guideline Panel was convened by the EHA Guidelines Committee and included hematologists, pediatricians, methodologists, and patient representatives with expertise in SCD and its complications. Panel members were assigned to thematic working groups based on their clinical expertise, and each group was responsible for drafting content and recommendations within their respective domains. Literature searches were conducted using PubMed for relevant studies published in English. A modified Delphi process was used to reach consensus on recommendations, and panel members voted anonymously using an online system. A predefined threshold of ≥70% agreement and <15% disagreement was required for adoption. Statements not reaching consensus were revised and subjected to further rounds of discussion and voting. Thirty‐five recommendations were adopted, including guidance on the use of hydroxyurea and therapeutic venesection.
INTRODUCTION
Sickle cell disease (SCD) is probably the commonest severe inherited disorder in the world. A Global Burden of Disease study estimated that 7–8 million adults and children have SCD, 1 although there is considerable uncertainty about the actual number. 2 More than 60% of affected people live in African countries, with significant numbers occurring in most other countries, including India, Brazil, most European countries, and the United States. 3
Outcomes vary markedly with geography. The majority of affected people die in childhood in Africa; outcomes in higher income countries are generally better but still involve a reduction of life expectancy of at least 20 years. 2
More than 15 different genotypes have been found to cause SCD, although most of these are rare. All genotypes involve the inheritance of at least one copy of the variant β‐globin gene producing sickle hemoglobin (HbS) (HBB; c.20A>T,p. Glu7Val). Homozygosity for HbS results in sickle cell anemia (SCA, HbSS), which is the most common form of the condition, although in populations of African origin about 30% of patients with SCD have hemoglobin SC disease (HbSC), in which HbS is co‐inherited with another βglobin variant, hemoglobin C (HbC) (HBB; c.19G>A, p.Glu7Lys). Up to two million people are estimated to have HbSC disease worldwide, mostly affecting people of West African origin, including large numbers of patients in North America, Brazil, and the Caribbean, and about 15,000 people in Europe. 4
Research and treatment guidelines have focused on HbSS, and to a lesser extent HbS/β0 thalassemia. HbSC disease has mostly been seen as a less severe and less important form of SCD, with the assumption that treatment recommendations for HbSS are also appropriate for HbSC. However, there is abundant and increasing evidence that HbSC is not just a mild form of HbSS but a separate condition with distinct pathological and clinical features. 5
The pathophysiology of HbSC is significantly different from HbSS, with red cells containing on average only about 50% HbS, which is far more similar to sickle cell carriers than HbSS. Although it is still not fully understood, HbS polymerization occurs at this low concentration because HbC binds to the red cell membrane, causing increased K‐Cl cotransporter activity with cation loss, red cell dehydration, and increased intracellular concentration of HbS. 6 , 7 Almost every laboratory parameter is significantly different in HbSC disease compared to HbSS, with HbSC having higher levels of total hemoglobin and mean cellular hemoglobin concentration (MCHC), and lower levels of most other factors including parameters reflecting rates of hemolysis (reticulocytes, lactate dehydrogenase, bilirubin), fetal hemoglobin levels (HbF), and inflammation (white cell count, neutrophil count, C‐reactive protein). The morphology of red cells on blood films is also strikingly different between the two conditions. 7 HbSC also has a distinctive clinical profile compared to HbSS, with approximately half the frequency of acute vaso‐occlusive pain (VOP), increased life expectancy, and an increased incidence of proliferative retinopathy and visual impairment. 5 The median survival of people with HbSC disease is unknown in most parts of the world but has been estimated at 80 years in the United Kingdom (compared to 62 for HbSS) 8 and 55 years in the United States (48 for HbSS), 9 although there is considerable uncertainty attached to these estimates.
As far as we know, there are currently no published guidelines specifically on the management of HbSC disease, and this guideline attempts to fill that gap. Although good quality evidence in this area is limited and makes it hard to give definitive recommendations, this guideline aims to provide a starting point for improved management of HbSC disease and to highlight specific areas where more evidence is needed. Most existing guidance includes HbSC only as a milder form of HbSS.
METHODS
This clinical practice guideline was developed by the European Hematology Association (EHA) in accordance with the EHA Guidelines Methodology Framework (EHA-Guidelines-Methodology). The objective was to provide consensus‐based guidance for the management of children and adults with HbSC disease.
A multidisciplinary Guideline Panel was convened by the EHA Guidelines Committee and included hematologists, pediatricians, methodologists, and patient representatives with expertise in SCD and its complications. Panel members were assigned to thematic working groups based on their clinical expertise, and each group was responsible for drafting content and recommendations within their respective domains.
Literature searches were conducted using PubMed for relevant studies published in English. In areas where direct evidence specific to HbSC disease was limited, broader data about other forms of SCD were considered. The search term “hemoglobin SC” was used and returned 877 relevant papers (between 1955 and 2026). Further searches were conducted combining the term “hemoglobin SC” with other terms, including “screening,” “retinopathy,” “hearing,” “otological,” “stroke,” “neurology,” “avascular bone necrosis,” “cardiology,” “thrombosis,” “anticoagulation,” “renal,” “liver,” “infection,” “Dengue,” “COVID,” “parvovirus,” “priapism,” “fat embolization syndrome,” “blood transfusion,” “phlebotomy OR venesection,” “bone marrow transplantation,” “gene therapy,” and “pregnancy.”
A modified Delphi process was used to reach consensus on recommendation statements. Panel members voted anonymously using an online system (www.welphi.com). A predefined threshold of ≥70% agreement and <15% disagreement was required for adoption. Not all participants voted on every statement and noncast votes were treated as abstentions. While partial voting occurred for some statements, the sample size was automatically adjusted so that the calculated consensus rates reflect only those participants who voted on each specific question. Statements not reaching consensus were revised and subjected to further rounds of discussion and voting. 10
All authors submitted declarations of interest, which were reviewed and managed in line with EHA policies. The final manuscript was reviewed and approved by all contributors prior to submission. The EHA Guidelines Office provided methodological and administrative support throughout the development process.
SCREENING AND PRENATAL DIAGNOSIS FOR HbSC DISEASE
There are numerous articles on antenatal screening for hemoglobinopathies. Most of the articles mention SCD without detailing phenotypes, and only three specifically mention HbSC disease. 11 , 12 , 13 Overall, the same recommendations regarding hemoglobinopathy screening apply to HbSC disease as to SCD in general.
Preconception and antenatal screening
Where health systems support it, preconception carrier screening is preferred so that reproductive options can be considered in advance. 14 , 15 The options available to individuals and couples after receiving genetic information have been addressed in other guidelines. 16 , 17
The choice of screening strategy should be adapted to national disease prevalence and the resources available within the health system. 11 Two main screening strategies are used:
Universal screening, suitable for high‐prevalence countries.
Selective screening, more appropriate in countries where the prevalence of hemoglobinopathies is very low, such as some countries in Northern Europe, 12 and in settings where healthcare resources are limited, where screening can focus on high‐risk groups.
Priority groups for SCD screening include women originating from Africa, the Caribbean, India, North Africa, the Middle East, Greece, and Turkey. Testing should be completed before 10 weeks, and the whole process, including testing of the biological father, should be completed within the first 12–13 weeks of pregnancy. 11
One difficulty is that many individuals or couples may be unaware that they have sickle cell trait, or even that SCD exists. Information may be provided by general practitioners, midwives, or obstetricians, who are often not very comfortable giving genetic information and counseling. 18 , 19 Wherever possible, information should be given by healthcare professionals with knowledge of HbSC disease.
Choice of tests
Various algorithms have been published to define screening pathways, depending on the prevalence of the conditions and available resources. These usually combine a complete blood count with hemoglobin analysis and confirmatory testing. Routinely used methods for hemoglobin analysis are able to reliably identify HbC, including high‐performance liquid chromatography, isoelectric focusing, mass spectrometry, and DNA analysis. More recently, point‐of‐care screening methods have been shown to contribute to the provision of preconceptual and antenatal screening in low‐ and middle‐income countries (LMICs), 20 and some of these are able to detect HbSC disease.
Prenatal diagnosis
Prenatal diagnosis may be performed by invasive sampling of chorionic villi or amniotic fluid at 10–12 and from 15 weeks of gestation, respectively. These tests have a >99% accuracy. They are performed in the United States, the United Kingdom, Europe, Asia, India, and the Middle East. 17 While some women consider these tests to pose a high risk of miscarriage, a recent meta‐analysis showed that the actual risk of miscarriage associated with the procedure is 0.3% after amniocentesis, while there is no significant risk associated with the chorionic villus sampling procedure. 21 Noninvasive prenatal tests that infer fetal genotype from cell‐free fetal DNA in maternal blood have been developed, but this technique is currently less accurate and not widely available. 22
Most people with HbSC have a milder form of SCD than those with HbSS and HbS/β0 thalassemia. Some doctors may decide not to inform couples in the case of HbSC risk, because they consider the condition to be mild. Two main points can be made: first, the choice to continue or terminate a pregnancy must be an informed decision made by the couple, based on their personal wishes; secondly, screening should enable individuals to make a choice, with one option being to prepare for the birth of a child with a chronic illness and another being to terminate the pregnancy. This is a complex issue, as HbSC can be severe in a minority of patients, and there are no early prognostic factors to indicate whether a fetus will have a severe form of HbSC.
The recently published EHA Guidelines have proposed that PND can be offered for phenotypes that are typically less severe than HbSS, such as HbSβ+ thalassemia and HbSC, as supported by a Delphi vote by a group of expert physicians from high‐ and low‐income countries, patients, and anthropologists. The consensus agreement was 94%. 16
Preimplantation genetic diagnosis may also be available for couples at risk of conceiving a baby with HbSC disease, and this should be discussed where possible.
Neonatal diagnosis
Newborn babies known to be at risk of having HbSC disease should be tested for the condition in the first few weeks of life, usually by hemoglobin analysis. Ideally, this would occur as part of a neonatal screening program in which all babies are tested for SCD, but in many countries this may involve selective testing based on the genotype of the mother or parents. Babies with confirmed HbSC disease should be referred to an appropriate clinic with a view to starting penicillin before 3 months of age, as for babies with other types of SCD. 16
Screening and prenatal diagnosis recommendations
-
1.
Screening programs for SCD should be able to detect both individuals with HbSC disease and couples at risk of conceiving a fetus with HbSC disease (16 agree, 0 disagree, 0 abstentions: 100% agreement).
-
2.
Prenatal diagnosis can be offered to couples at risk of conceiving a fetus with HbSC disease (15 agree, 0 disagree, 1 abstention: 100% agreement).
INFORMATION AND COUNSELING FOR HbSC DISEASE
It is important that specific information and counseling are provided about HbSC disease, including to people with the condition, couples at risk of conceiving a fetus with HbSC disease, and to parents/families of affected children and babies. The nature of the counseling and the information given will depend on the healthcare setting and should be appropriate to the resources and options available in that area.
Antenatal and prenatal genetic counseling should specifically address the pattern of disease seen in HbSC disease rather than HbSS to allow couples to make informed reproductive choices. Counseling should include that HbC carriers are asymptomatic and that people homozygous for HbC (HbCC) may have mild hemolytic anemia and splenomegaly but do not have a clinically significant condition. Similarly, parents of neonates with HbSC should be informed about the natural history of HbSC disease with the expectation that the majority of people have few or no problems during childhood. We recommend that written information includes specific information about HbSC disease rather than a generic account of SCD, although little such information is currently available.
There is a need for more education and awareness about HbSC disease. While the phenotype may be milder than HbSS, cumulative complications impair long‐term health. 23 , 24 The variable phenotype of HbSC disease requires counseling that addresses not only the clinical presentation but also the psychosocial dimensions of this condition, which are often unrecognized. Studies show that many parents receiving a prenatal diagnosis of SCD experience significant anxiety, highlighting the necessity of incorporating psychological support into counseling protocols, 25 although this may be more difficult in low‐resource settings.
Information and counselling for HbSC disease recommendations
-
1.
Specific counseling should be provided about HbSC disease to couples, families, and individuals affected by the condition (16 agree, 0 disagree, 0 abstentions: 100% agreement).
-
2.
Written information with specific details of HbSC disease should be produced and provided to relevant people as appropriate (16 agree, 0 disagree, 0 abstentions: 100% agreement).
-
3.
Geneticists, nurses, and other counselors should be trained about HbSC disease and able to provide appropriate information about the condition (16 agree, 0 disagree, 0 abstentions: 100% agreement).
MANAGEMENT OF CHRONIC COMPLICATIONS IN HbSC DISEASE
Retinopathy
Sickle cell retinopathy occurs in 15%–20% of adult patients with HbSS and in 33%–40% of those with HbSC. 26 Proliferative sickle retinopathy (PSR) is characterized by abnormal neovascularization in the retina, typically resulting from excessive growth of blood vessels, and is less common than non‐PSR (NPSR). An 11‐year follow‐up study in adults with HbSC found that at a mean age of 23 years, 28.3% of HbSC patients had proliferative retinopathy, which increased to 47.8% after a mean follow‐up of 11 years. In HbSS and HbS/βthalassemia patients, these numbers were 4.8% at baseline, with an increase to 10.8% after 11 years. 27
PSR may first appear in late childhood, with peak incidence occurring in the third and fourth decades of life. 28 One hypothesis for the higher prevalence of PSR in HbSC suggests that while peripheral retinal vessel occlusion occurs, a minimal level of oxygenation persists, sufficient to promote neovascularization. In contrast, in HbSS, more extensive retinal ischemia may suppress new vessel formation. 6 PSR in HbSC appears to be more strongly linked to blood viscosity than to hemoglobin or RBC density, reflecting red blood cell (RBC) rheology and hemoglobin concentration. 29 , 30 Proliferative neovascularization can result in significant loss of vision, typically through vitreous hemorrhage or tractional retinal detachment. Although there is currently no intervention that is known to alter the natural history of early retinopathy, early identification may be useful to inform families and allow closer clinical monitoring.
Children with HbSC disease should start annual fundus examination from 10 years of age, with urgent referral for expert management in case of acute visual symptoms or progressive loss of vision. Management of retinopathy in SCD is currently based on laser photocoagulation, with emerging evidence on the use of antivascular endothelial growth factor. 31
Retinopathy recommendations
-
1.
People with HbSC disease should have a formal annual retinal examination from 10 years of age, with urgent referral for expert management in case of acute visual symptoms or progressive loss of vision (14 agree, 0 disagree, 2 abstentions: 100% agreement).
Neurological complications
Neurological complications (ischemic stroke, hemorrhagic stroke, and silent cerebral infarcts) are common in SCD. 32 The risk of stroke in children with HbSC disease is 50–100 times greater than that of the general pediatric population, with an estimated prevalence of overt stroke of 2% and of silent cerebral infarcts ranging from 8% to 13.5% 33 , 34 , 35 , 36 , 37 by the age of 16 years. Although the overall incidence of stroke is lower in individuals with HbSC compared to those with HbSS, stroke rates in HbSC peak later in life, particularly among older adults, with hemorrhagic stroke being more prevalent. 32 , 38
Transcranial Doppler (TCD) velocities are lower in children with HbSC than in HbSS, 39 , 40 with the 98th centile for time‐averaged mean velocity being about 130 cm/s, although there is little evidence on how TCD screening should be used in HbSC. Stroke and cerebrovascular disease should be considered in children with HbSC and neurological symptoms or cognitive impairment, and investigation should include neuropsychological assessment, TCD scanning, and MRI/MRA as appropriate.
In general, children and adults with HbSC disease presenting with acute stroke should be treated similarly to patients with SCA. 41 Risk factors for stroke in the general population, including increasing age, hypertension, diabetes, atrial fibrillation, hyperlipidemia, hypercoagulability, and renal disease, also contribute to the risk in adults with HbSC 38 and should be managed accordingly. The management of an acute stroke in a patient with HbSC should involve multidisciplinary management, including staff with expertise in SCD and acute stroke, and be guided by their stroke risk factors, the etiology of the stroke, and the clinical history. Prompt treatment with thrombolysis may be appropriate for some adult patients, and this may need to be followed by long‐term blood transfusions, which typically will involve exchange transfusion because of the high baseline hemoglobin levels in people with HbSC disease.
Full assessment of all HbSC patients presenting with stroke should be undertaken after the acute treatment is complete, to inform the need for long‐term transfusion and secondary stroke prevention. Standard risk factors for stroke should be managed and may include agents, such as statins and antiplatelet agents. 42 , 43
Neurological complications recommendations
-
1.
The risk of stroke and cerebrovascular disease should be assessed in people with HbSC disease when there is concern about neurological symptoms or cognitive function, including neuropsychological testing and brain MRI/MRA (15 agree, 0 disagree, 1 abstention: 100% agreement).
-
2.
In adults with HbSC disease, management of standard risk factors for stroke should be guided by medical and stroke teams and may include antihypertensives, statins, and antiplatelet agents (14 agree, 0 disagree, 2 abstentions: 100% agreement).
Avascular bone necrosis
Osteonecrosis, also known as avascular necrosis (AVN), is a frequent complication in individuals with HbSC disease, with an estimated prevalence ranging from 12% to 24%, similar to that observed in patients with HbSS. 5 , 44 , 45 AVN most commonly affects large weight‐bearing joints, particularly the hips (1.9 cases per 100 patients) and shoulders (1.7 cases per 100 patients), although other joints, including the spine, may also be involved. The condition typically manifests after the age of 25 and is rarely seen in younger patients. The pathogenesis of AVN in HbSC is not fully understood, but some weak evidence suggests that blood hyperviscosity may be involved. 46 , 47 AVN typically manifests as focal pain but may trigger more generalized acute pain and should be suspected when localized pain persists. MRI is the most sensitive imaging modality for detecting and assessing the extent of joint damage, but where MRI is not available, plain X‐rays are useful in symptomatic patients. The main goals of AVN management are pain control and preservation of function. There are no studies focusing primarily on HbSC disease, but some evidence supports the use of bisphosphonates 48 and the local injection of mesenchymal stem cells 49 for AVN in SCD in general. Physiotherapy plays an important role in managing symptoms, with surgical joint replacement reserved for progressive disease. 50
Avascular bone necrosis recommendations
-
1.
MRI should be used to diagnose avascular bone necrosis if chronic pain develops in the hips or shoulders (14 agree, 0 disagree, 2 abstentions: 100% agreement).
Cardiovascular disease
Although people with HbSS have lower systemic blood pressures than controls, 51 studies in HbSC have shown a higher incidence of systemic hypertension. Lionnet et al. studied 179 patients with HbSC and found that high blood pressure (>130/80 mmHg) was present in 14% of patients, which may be associated with higher body mass indices. 44 , 52 , 53 In a prospective study of pulmonary hypertension in SCD, Gladwin et al. reported significantly lower tricuspid regurgitant jet velocities (TRJV) in individuals with HbSC disease, possibly reflecting higher hemoglobin levels and the lower rate of hemolysis in this group. 54
Cardiac involvement is well documented in HbSS, but less is known about it in HbSC disease. Guedeney et al. compared results of echocardiographic measurements of 60 HbSC patients (median age 31 years, 25 men) with 60 HbSS patients and 60 matched healthy controls. 55 Both HbSS and HbSC patients showed increased left ventricular mass index compared to controls, although left ventricular hypertrophy was rare in HbSC patients (5%) but common in SCA patients (45%, P < 0.0001). HbSC patients also had cardiac index and tricuspid regurgitation velocities similar to controls, unlike HbSS patients. Left ventricular ejection fraction was comparable across all groups. 55 In SCA, cardiac changes were mainly associated with anemia and hemolysis. In contrast, in HbSC disease, diastolic dysfunction and elevated TRV were linked to comorbidities like hypertension and being overweight. Based on this, blood pressure and cardiac function should be monitored in HbSC disease 55 with electrocardiograms where appropriate. Cardiac function should be assessed by echocardiogram between the ages of 16 and 18 years and repeated every 3 years. Limited resources may make this impractical in many countries, in which case echocardiograms should be offered to patients at high risk of cardiac disease or with significant symptoms.
Cardiovascular disease recommendations
-
1.
A baseline echocardiogram should be performed between ages 16 and 18, followed by repeat evaluations every 3 years in the absence of additional risk factors (e.g., elevated body mass index, hypertension, or diabetes). Abnormal echocardiograms should be monitored annually for progression (13 agree, 1 disagrees, 2 abstentions: 93% agreement).
Thrombosis
Individuals with HbSC have increased rates of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). 56 Retrospective cohort studies have reported that non‐catheter‐related VTE occurs more frequently in HbSC patients than in those with HbSS. 44 , 57 In an autopsy series involving 44 individuals with HbSC, PE was identified as the second leading cause of death. 58 More recently, Nelson et al. reported a similar prevalence of PE in patients with HbSC disease (8.6%) and those with SCA (8.5%). 5 Risk factors for VTE in HbSC include elevated hemoglobin and a history of splenectomy. 59 A higher incidence of death was seen in patients with COVID‐19 and HbSC (and HbS/β+thalassemia) compared to HbSS (11.9% case fatality rate versus 5.2%), which has been partly attributed to an increased incidence of VTE in HbSC patients. 60 Although the evidence is limited, based on these high rates of VTE in HbSC disease, we recommend that all patients with HbSC over the age of 12 years admitted to hospital are given prophylactic anticoagulation, unless there are contraindications. Prophylactic anticoagulation may be used in some younger children with other risk factors for thrombosis and should be stopped on discharge from hospital.
Thrombosis recommendations
-
1.
All patients with HbSC disease over the age of 12 admitted to hospital should be given prophylactic anticoagulation unless contraindicated (14 agree, 0 disagree, 2 abstentions: 100% agreement).
-
2.
Patient education should include strategies for VTE prevention (15 agree, 0 disagree, 1 abstention: 100% agreement).
Renal disease
Renal complications in individuals with HbSC disease are less frequent than in those with HbSS, tend to occur later in life, and progress more gradually. 44 Common manifestations include hyposthenuria, acute papillary necrosis, and microalbuminuria. Sickle cell nephropathy in HbSC is clinically and pathophysiologically distinct from that seen in HbSS. In HbSC, renal involvement usually presents in adulthood and rarely progresses to end‐stage renal disease (ESRD). 44 , 61 Microalbuminuria is reported in approximately 30% of patients with HbSC, while ESRD develops in only 2%–3% of individuals by their fifth decade of life. 44 , 62 , 63
Children with HbSC disease typically develop irreversible hyposthenuria between the ages of 10 and 15 years, reflecting early impairment in urinary concentrating ability. Evidence of both glomerular damage and medullary injury has been observed in this population, indicating the onset of progressive renal involvement during adolescence. 62 , 64
We recommend that where resources permit, annual screening for kidney disease should start at the age of 10 in all children with HbSC disease. This should include eGFR and urine albumin to creatinine ratio. In the presence of additional risk factors such as diabetes and hypertension, the frequency of blood and urine tests should be increased. In patients with significant renal impairment, management should include a nephrologist with an interest in SCD.
Renal disease recommendations
-
1.
Annual screening for kidney disease should be started in all children with HbSC disease from the age of 10, including eGFR and albumin‐to‐creatinine ratio (16 agree, 0 disagree, 0 abstentions: 100% agreement).
-
2.
In patients with significant or progressive renal impairment, multidisciplinary management should include a nephrologist with a specialist interest in SCD (15 agree, 0 disagree, 1 abstention: 100% agreement).
Liver disease
Gallbladder‐related complications are significantly less frequent in people with HbSC disease (15%–20%) compared to those with HbSS (up to 50%), probably due to lower rates of hemolysis. 5 , 65 , 66 Cholelithiasis is found in approximately 3% of children with HbSC under 14 years, rising to nearly 20% by the age of 20 65 ; the co‐inheritance of alpha‐thalassemia trait has been associated with a reduced prevalence and delayed onset of symptomatic gallbladder disease. 66
Patients with HbSC disease who develop significant liver disease are likely to have another co‐existent problem, such as infectious hepatitis or autoimmune liver disease, which is increasingly diagnosed in people with SCD.
Liver function should be monitored at least once a year with liver biochemistry, ideally involving the measurement of albumin, ALT, AST, γ‐GT, and total bilirubin, although this may vary according to local resources and availability. Ultrasound of the liver and transient elastography may be useful to screen for liver disease, although their value in HbSC disease is not defined, and their use will depend on available resources. In persistent or progressive liver disease, further investigations should include imaging of the liver and involve a hepatologist with a particular interest in SCD.
Liver disease recommendations
-
1.
Liver function should be monitored at least once a year with liver biochemistry (AST, ALT, γGT, bilirubin) (14 agree, 1 disagrees, 1 abstention: 93% agreement).
-
2.
In the presence of persistent or progressive liver disease, further investigations should include imaging of the liver and the involvement of a hepatologist with a particular interest in SCD (15 agree, 0 disagree, 1 abstention: 100% agreement).
Spleen
Splenic function is partially preserved during the first decade of life in children with HbSC 67 , 68 although penicillin prophylaxis is still typically started at 3 months of age, as for HbSS. Functional asplenia is observed in approximately 45% of individuals with HbSC disease by the age of 12 years. 67 About 33% of people with HbSC have chronic splenomegaly compared to 22% of people with HbSS. 5 Splenomegaly is associated with mild thrombocytopenia in up to 35% of children and 50% of adults. Chronic splenomegaly may also present with recurrent abdominal pain, splenic infarctions, and symptoms attributable to hypersplenism, which can complicate or limit the efficacy of disease‐modifying therapies, such as blood transfusions and hydroxyurea. 69 , 70 Although the risk of infection is probably less in young children with HbSC compared to those with HbSS, protocols for penicillin, on‐demand antibiotic treatment, and vaccinations in HbSC should be the same as those for HbSS.
Spleen recommendations
-
1.
Although the risk of infection is probably less in young children with HbSC disease compared to those with HbSS, protocols for penicillin and vaccinations in HbSC should be the same as those for HbSS (14 agree, 1 disagrees, 1 abstention: 93% agreement).
Priapism
Priapism affects 30%–45% of men with HbSS and 10%–20% of men with HbSC, although there are few studies. 5 , 44 As in HbSS, priapism frequently presents during adolescence or early adulthood, coinciding with the onset of sexual maturity. 71 In some cases, priapism may be the first clinical manifestation of HbSC. 72
All male patients with HbSC should be educated to recognize priapism and be advised on simple measures to undertake at home to resolve it, including mild exercise, a hot bath or shower, and micturition.
The approach to management of acute priapism in individuals with HbSC should follow a similar multidisciplinary approach as for patients with HbSS, involving urologists and hematologists. 73 Ischemic priapism can cause irreversible erectile dysfunction with fertility problems if it extends beyond 4 h. 74
Priapism recommendations
-
1.
All male patients with HbSC should be educated to recognize priapism and advised on simple measures to undertake at home to resolve it, including mild exercise, a hot bath or shower, and micturition (15 agree, 0 disagree, 1 abstention: 100% agreement).
-
2.
Acute priapism in people with HbSC disease should follow a similar multidisciplinary approach as used in patients with HbSS, involving urologists and hematologists (15 agree, 0 disagree, 1 abstention: 100% agreement).
DISEASE‐MODIFYING TREATMENTS
Blood transfusion
There are few or no studies specifically addressing the role of blood transfusion in HbSC disease. In general, the same guidelines apply as in HbSS, 75 with the potential benefits of blood transfusion arising from the correction of anemia and dilution of the number of circulating red cells able to cause vaso‐occlusion or hemolysis. Patients with HbSC disease are typically less anemic than those with HbSS and so are more likely to need exchange transfusion rather than simple top‐up to achieve appropriate hemoglobin and percentage Hb(S + C) targets. Post‐transfusion targets for different hemoglobins should be based on combined totals of HbS and HbC, rather than HbS alone; for example, the equivalent of an HbS target <30% would be (HbS + HbC) <30%.
No study has established specific recommendations regarding phenotypic matching for blood transfusion in patients with HbSC disease. Most studies on alloimmunization and delayed hemolytic transfusion reaction (DHTR) include HbSC and HbSS patients, with no statistically significant differences according to genotype. However, one study from Brazil showed that HbSC patients get alloimmunized more often than HbSS patients, 76 possibly because HbSC patients tend to be transfused at an older age, less frequently and in more acute situations. 77 Established recommendations should apply to patients with both HbSS and HbSC, with no distinction between these two groups. The ASH guideline panel recommends prophylactic red cell antigen matching for Rh (C, E or C/c, E/e) and K antigens in addition to ABO/RhD matching for patients with all SCD genotypes, and extended red cell antigen matching (Jka/Jkb, Fya/Fyb, S/s) may provide further protection from alloimmunization, especially in patients already immunized, 75 although this may not be possible in countries without blood transfusion services.
Finally, in patients at high risk of posttransfusion hemolysis (transfusion for acute complication and with a history of immunization and DHTR), it is recommended to avoid transfusion if possible and to use immunosuppressive drugs, such as rituximab, to prevent DHTR and production of new alloantibodies. 75 , 78
Blood transfusion recommendations
-
1.
Posttransfusion targets for different hemoglobins should be based on combined totals of HbS and HbC, rather than HbS alone; for example, the equivalent of an HbS target <30% would be (HbS + HbC) <30% (14 agree, 0 disagree, 2 abstentions: 100% agreement).
-
2.
In blood transfusion, red cell antigens should be matched for Rh (C, E or C/c, E/e) and K antigens in addition to ABO/RhD matching for patients with HbSC disease. Extended red cell antigen matching (Jka/Jkb, Fya/Fyb, S/s) may provide further protection from alloimmunization (13 agree, 0 disagree, 3 abstentions: 100% agreement).
Hydroxyurea
The mechanisms of action of hydroxyurea in HbSC are unknown, but may include increasing HbF, induced macrocytosis, and reduced neutrophil levels. 79 , 80 Hydroxyurea may increase total hemoglobin levels in some people. Additionally, a higher frequency of hypersplenism in HbSC combined with a lower platelet count has raised concern about dose‐limiting cytopenias. 3 The shortage of data regarding the benefits of hydroxyurea in HbSC has limited its use. 81
Retrospective observational studies have suggested some clinical benefit and low toxicity of hydroxyurea in both children and adults with HbSC. 82 , 83 The largest retrospective study reported the beneficial effects of hydroxyurea in 133 adults and children with HbSC, given mainly for reducing recurrent VOP. In these patients, hydroxyurea treatment was associated with a stable Hb concentration, increased HbF and MCV, and reduced white blood cell, neutrophil, and reticulocyte counts. Reversible cytopenias occurred in 22% of patients, primarily neutropenia and thrombocytopenia. Painful events (clinic, emergency department, and hospital) were reduced by 38% with hydroxyurea. 84
The only randomized placebo‐controlled trial with HU in patients with HbSC is the PIVOT study (Prospective Identification of Variables as Outcomes for Treatment), 85 , 86 a phase II trial of hydroxyurea versus placebo in Ghana for patients aged 5–50 years. The primary outcome was the cumulative incidence of hematologic dose‐limiting toxicities (DLTs), including cytopenias or elevated Hb levels during 12 months of blinded treatment. Secondary endpoints included VOP events, acute chest syndrome (ACS), hospitalizations, transfusions, and malaria. Two hundred and twelve eligible participants initiated blinded treatment at 20.0 ± 5.0 mg/kg/day randomized to either hydroxyurea or placebo. DLTs occurred in more participants on hydroxyurea (33%) than placebo (11%) (95% confidence interval for difference [CI], 11%–34%), which exceeded the predefined 15% noninferiority margin, although most DLTs were mild and transient. There was no difference in the number of patients with elevated levels of Hb between the groups (12 participants on hydroxyurea and 10 on the placebo). However, hydroxyurea treatment was associated with 57.0 versus 149.6 VOP events per 100 person‐years (incidence rate ratio [IRR] 0.38; 95% CI, 0.28–0.52) and 12.9 versus 30.6 hospitalizations per 100 person‐years (IRR 0.42; 95% CI, 0.22–0.81).
Although the evidence is limited, hydroxyurea seems to be well tolerated in patients with HbSC disease and effective at reducing the frequency of acute VOP and hospital admission. Based on data from the PIVOT trial, a starting dose of 20 mg/kg/day with dose escalation up to 25 mg/kg is clinically beneficial in both adults and children over 5 years of age (treatment algorithm in Figure 1, https://hbsc.hemoglobin.dk). Hydroxyurea should be offered after more than one significant episode of pain, although this may vary, particularly in LMICs where resources for providing and monitoring hydroxyurea are more limited.
Figure 1.

Summary of guidelines for management of patients with symptomatic HbSC disease (available at https://hbsc.hemoglobin.dk ).
Hydroxyurea recommendations
-
1.
Hydroxyurea should be considered in children and adults with HbSC disease if they have more than one significant episode of acute pain (13 agree, 2 disagree, 1 abstention: 87% agreement).
-
2.
Hydroxyurea should be prescribed at a starting dose of 20 mg/kg, which may be increased/decreased, depending on efficacy and toxicity (12 agree, 1 disagrees, 3 abstentions: 92% agreement).
Phlebotomy
A few studies have indicated benefit of phlebotomy in older children and adults with HbSC. The mechanism of action is unclear, but it is thought to induce iron‐restricted erythropoiesis, causing reductions in MCHC, hemoglobin levels, and whole blood viscosity. There is some evidence that HbSC patients with iron deficiency have reduced episodes of acute pain. 87 , 88 Theoretically, it may be a particularly appropriate treatment for patients with higher hemoglobin levels and significant symptoms, such as frequent episodes of pain, retinopathy, or sensorineural hearing loss. A retrospective, nonrandomized study of 64 HbSC patients with clinical complications, including pain, ACS, priapism, and thrombosis, reported clinical improvement in 71% after serial phlebotomy. 44 , 89
Although no randomized trial has been undertaken to show the efficacy of phlebotomy in HbSC disease, there is insufficient evidence to suggest whether hydroxyurea or phlebotomy should be offered first, and preferences will depend on local resources and patients' wishes. Dual therapy with hydroxyurea and phlebotomy may also be an effective approach. A study found HbSC patients who did not gain clinical improvement with hydroxyurea alone benefited from added phlebotomy. Five out of 11 patients with HbSC who achieved MTD but failed to demonstrate clinical improvement on hydroxyurea were placed on dual hydroxyurea and phlebotomy therapy, and 4 of the 5 showed at least some clinical improvement. 90
Phlebotomy has also been used as a treatment for some acute complications of HbSC disease, such as vertigo and acute hearing loss, and based on anecdotal experience, acute venesection to cause a rapid fall in hemoglobin level may be useful in some circumstances (Figure 1).
Benefits from venesection need to be balanced against the side‐effects of iron deficiency, including reduced quality of life and concern about the effects on cognitive development in children, 91 and for these reasons it is recommended that venesection is only considered after the age of 12 years.
There is little evidence to support any one particular method of venesection, and it seems appropriate to use the protocol in the largest study 44 , 89 :
Eligibility: Age ≥12 years old, Hb >10.5 g/dL experiencing at least one of ACS, acute painful episode requiring medical intervention, priapism, otological disorders, and splenic infarction.
Protocol: Weekly venesection until a hemoglobin target of 9.5 g/dL or iron deficiency (ferritin <50 μg/L) is reached, with phlebotomy performed intermittently thereafter to keep hemoglobin between 9.5 and 10.5 g/dL or ferritin <50 µg/L, with a 2–3‐month monitoring schedule.
The precise ferritin threshold to determine iron deficiency in SCD 92 is unknown and some protocols use a lower target ferritin, such as <20 μg/L, and may use other parameters to monitor the effects, such as MCHC.
Phlebotomy recommendations
-
1.
Phlebotomy should be considered for patients ≥12 years old with HbSC disease and significant symptoms, including episodes of acute pain, ACS, otological disorders, priapism, and involve regular venesections to maintain the hemoglobin between 9.5 and 10.5 g/dL or to induce iron deficiency (12 agree, 1 disagrees, 3 abstentions: 92% agreement).
-
2.
Phlebotomy to produce an acute reduction in hemoglobin should be considered in patients presenting with acute hearing loss or vestibular symptoms (13 agree, 1 disagrees, 2 abstentions: 93% agreement).
-
3.
Phlebotomy can be combined with hydroxyurea if patients remain symptomatic on a single treatment (12 agree, 1 disagrees, 3 abstentions: 92% agreement).
Other drugs
No other drugs have an established role in treating HbSC disease, although crizanlizumab 93 and l‐glutamine 94 are available in the United States and other drugs are undergoing clinical trials 95 , 96 , 97 (Table 1).
Table 1.
Other drugs of potential use in HbSC disease.
| Drug | Summary of Evidence in HbSC Disease | Availability |
|---|---|---|
| l‐glutamine | Some efficacy suggested in HbSS, no supporting evidence for use in HbSC. Only one HbSC patient reported in clinical trials. | Licensed for use in the United States and some other countries but not in Europe |
| Crizanlizumab | Mechanism blocks P‐selectin; HbSC included in studies but <20 patients and no proven efficacy in HbSC. Phase 3 study did not show benefit and further study is being undertaken. | Licensed for use in the United States and some other countries but not in Europe |
|
Pyruvate kinase activators |
Trials allow HbSC participants, but exclusion of Hb >10.5 g/dL limits eligibility. No current evidence of benefit for HbSC. |
Available in clinical trials |
|
Drugs inducing iron‐restricted erythropoiesis |
Early‐phase clinical trials in process of ferroportin inhibitors (vamifeport 96 ) and hepcidin mimetics (PN23314 98 ) |
In development |
MANAGEMENT OF ACUTE COMPLICATIONS
Acute VOP
Treatment of acute VOP in patients with HbSC is similar to that described in guidelines for SCD in general and involves adequate analgesia administered within 30 min of presentation. 99 A personal pain plan is recommended as well as nurse‐based initiation of treatment to prevent delay. 100 Initiation of thrombosis prophylaxis is recommended in adult patients admitted with VOP. 44 , 56 , 57
Acute VOP recommendations
-
1.
Acute painful episodes should be managed as for HbSS and other forms of SCD (14 agree, 0 disagree, 2 abstentions: 100% agreement).
ACS
ACS is probably less severe in people with HbSC compared to those with HbSS, but still causes significant morbidity and mortality. 101 , 102 Asthma seems to be a particular risk factor for ACS in children with HbSC disease. 101 Broad‐spectrum antibiotics and oxygen (if oxygen saturation is <95%) are advised, with careful fluid balance to prevent further deterioration of pulmonary function due to fluid overload. Top‐up transfusions are often not appropriate given the higher hemoglobin level in HbSC patients. Exchange transfusion is advised in patients with progressive deterioration and hypoxia despite adequate oxygen supplementation. 102 The number of red cell units should be calculated to reduce the (HbS% + HbC%) level to less than 30% and to increase the hemoglobin level to 10 g/dL or higher, depending on the steady‐state hemoglobin of the patient.
ACS recommendations
-
1.
Exchange transfusion should be used in patients with progressively worsening ACS, with a target hemoglobin of 10 g/dL and (HbS + HbC) <30% (14 agree, 1 disagrees, 1 abstention: 93% agreement).
Acute splenic sequestration and splenic infarction
Splenic sequestration affects 6%–12% of children with HbSC; it is less common than in HbSS but occurs at an older age, including in adults. 69 , 103 Acute treatment is similar to that for HbSS and involves treatment of hypovolemic shock and transfusion in case of severe anemia. Preventive splenectomy should be considered in all patients with a history of severe or recurrent splenic sequestration, including adults. 104
Splenic infarction can occur spontaneously or be triggered by high altitude, and in patients with HbSC and acute abdominal pain, investigations should include abdominal ultrasound. 70
Acute splenic sequestration recommendations
-
1.
Acute splenic sequestration can occur in older people and adults and should be treated as recommended for patients with HbSS (15 agree, 0 disagree, 1 abstention: 100% agreement).
Viral infections
Although, in general, infective complications are less severe in HbSC than in HbSS, some viral infections have been found to have worse outcomes in HbSC. Dengue fever, 105 , 106 COVID‐19, 60 and parvovirus B19 107 , 108 are perhaps the three most important examples of this, and people with HbSC should be warned about these infections and vaccinated where possible.
Dengue fever
Climate change has increased the distribution of dengue to previously dengue‐naive countries. 105 HbSC patients are at particular risk of severe and fatal dengue. People with HbSC in regions where there is a high risk of dengue should be warned of the increased risk of severe and even fatal infection and encouraged to seek medical attention early if there are symptoms consistent with dengue. 105 , 106 Patients who live in or travel to endemic areas who present with symptoms and/or signs of dengue should be tested early and observed closely as they may need inpatient care and transfusions.
COVID‐19
As for the general population, age is a critical determinant of outcomes with COVID‐19 in people with HbSC disease. In children with HbSC disease, the mortality risk of COVID‐19 does not seem to be increased compared to normal. 109 However, in adults, some studies suggested an increased risk of death in HbSC disease compared to those with HbSS and also the non‐sickle population. 60 People with HbSC disease should be considered at increased risk of severe COVID‐19 infection, and vaccination against COVID‐19 infection is recommended, depending on local guidance.
Parvovirus B19
People with HbSC disease are less likely to present with severe anemia requiring blood transfusion than those with HbSS following Parvovirus B19 infection, but seem more likely to develop other severe complications, including bone marrow necrosis and fat embolism syndrome. 108 People with HbSC should be warned of potential complications of Parvovirus B19 infection and monitored closely, particularly during epidemics or when other family members have been diagnosed with the condition. 107
Fat embolism syndrome
Fat embolism syndrome is a poorly defined complication of SCD involving acute lung damage, neurological complications, and multiorgan failure, with evidence of bone marrow necrosis, although there are no clear diagnostic criteria. It seems to disproportionately affect less severe forms of SCD, with 40%–50% of cases involving HbSC disease. Historically, more than 50% of cases have died. The most effective treatment seems to be red‐cell exchange transfusion, with possible further benefits from plasma exchange 108 ; these can be performed sequentially or combined as a whole‐blood exchange transfusion.
Fat embolism recommendations
-
1.
Fat embolism syndrome with bone marrow necrosis is more common in HbSC disease and should be managed with early exchange transfusion, and possibly plasma exchange in severe cases (14 agree, 1 disagrees, 1 abstention: 93% agreement).
Acute hearing loss
Hearing loss and otological disorders are more common in HbSC than HbSS, with 29% of adults having significant hearing impairment in one study 44 ; a small study also found that 35% of children with HbSC had hearing loss. 110 Cochlear infarction is thought to underlie much of this morbidity and seems to be linked to the presence of retinopathy.
Although there is little evidence on how to manage this complication, both exchange transfusion and urgent venesection to reduce the hemoglobin level have been used, and specialist input from otologists is important. Corticosteroids are typically used in acute hearing loss in the general population and may be used in HbSC disease, although there is no evidence. We suggest that audiology testing should be available to children and adults with HbSC disease with possible hearing loss, and treatment considered in people with evidence of otherwise unexplained sensorineural hearing impairment, which may involve regular venesection or regular blood transfusions to keep the level of (HbS + HbC) below 30%. The effects of hydroxyurea on sensorineural hearing loss seem variable, with one study suggesting that it may increase the risk of hearing loss in SCD. 110 Typically, acute hearing loss in HbSC disease is irreversible, reflecting cochlear infarction rather than the inflammatory process seen in the nonsickle population.
Acute hearing loss recommendations
-
1.
People with HbSC disease should have access to audiology testing (12 agree, 0 disagree, 4 abstentions: 100% agreement).
PREGNANCY
Pregnancy in SCD in general carries high maternal and fetal risks. Preconception counseling and multidisciplinary care are important. All maternity units should have SCD protocols, links to specialist hemoglobinopathy teams, and staff training on SCD. 111 There is very little evidence specifically about HbSC disease; further trials are needed to define optimal care strategies in HbSC disease.
Limited studies suggest that pregnancy outcomes in HbSC disease are better than in HbSS, with a study in Jamaica suggesting similar outcomes to a control population without SCD, although women with HbSC disease had less weight gain and smaller babies. 112
Antenatal care should follow the guidelines for patients with SCD in general. 113 This should involve a multidisciplinary team, including a hematologist, obstetrician, transfusion specialist, and midwife with experience of managing patients with HbSC disease. Care should include aspirin 150 mg from 12 to 36 weeks, iron supplementation if ferritin <30 µg/L, and monthly growth scans from 24 weeks. In the United Kingdom, expert opinion recommends low molecular weight heparin from 28 to 6 weeks postpartum, and during any antenatal admission, although there is little evidence to support this and it is not practised in many countries. Prophylactic blood transfusion is not routinely recommended but may be necessary in women with a history of frequent pain, life‐threatening complications, or progressive organ damage. Because of the higher baseline hemoglobin in HbSC disease, exchange rather than top‐up transfusion is more likely to be necessary than in HbSS. Acute complications of HbSC should be managed according to guidelines with the involvement of both obstetric and hematology teams.
Intrapartum care should involve delivery between 38 and 40 weeks if the fetus is growing normally to reduce late‐pregnancy risks. Vaginal birth is preferred unless there are obstetric indications for Cesarean section. Labor should be in hospital with multidisciplinary care and continuous fetal monitoring. 113 Epidural analgesia is safe in HbSC and regional anesthesia is preferred if Cesarean is necessary.
Pregnancy recommendations
-
1.
Pregnancy should involve both obstetric and hematologic clinical teams with experience of caring for patients with HbSC disease and follow guidance provided for the care of pregnancy in SCD in general (15 agree, 0 disagree, 1 abstention: 100% agreement).
STEM CELL TREATMENTS
Hematopoietic stem cell transplantation
Data on HSCT in people with HbSC is limited. The European Society for Blood and Bone Marrow Transplantation (EBMT) Hemoglobinopathy Registry reported two multicentric multinational studies respectively on more than 2000 patients with SCD transplanted between 2000 and 2021, 114 , 115 but with no data on outcomes based on genotypes. A few small studies of HSCT in SCD have been reported but again with no data on outcomes related to genotype. 116 , 117 , 118 Based on this very limited data, the indications for HSCT in patients with HbSC should be the same as for HbSS and will most often be frequent episodes of acute pain not responding to treatment. Some guidelines suggest that having an HLA‐identical sibling is an indication for HSCT in young children with HbSS irrespective of symptoms, although this is not recommended as an indication for HSCT in HbSC disease.
Hematopoietic stem cell transplantation recommendations
-
1.
Indications for HSCT in patients with HbSC disease should be the same as for HbSS, and other types of sickle cell disease (12 agree, 1 disagrees, 3 abstentions: 92% agreement).
Gene therapy
To date, clinical studies of gene therapy have excluded subjects with HbSC disease. Although no data are available to define the benefit/risk for people with HbSC disease, neither the FDA nor the EMA restricted the use of gene therapies to specific types of SCD. However, the consensus EHA‐EBMT document does not currently recommend gene therapy in HbSC disease. 119 Given the different cellular pathology of HbSC compared to HbSS, it is difficult to predict how useful either the addition of β‐globin or promotion of HbF might be, although new approaches involving the direct correction of the HbS mutation using prime and base editing are emerging and are likely to benefit patients with HbSC disease. 120 Gene therapy is currently not recommended for patients with HbSC.
RESEARCH
The accuracy and scope of these guidelines are limited by the lack of research on HbSC disease. Happily, more research seems to be occurring in this area, with the development of mouse models and erythroid cell lines expressing HbSC, 80 , 121 and clinical trials specifically for people with HbSC. 85 Hopefully, this progress will continue and facilitate better understanding of HbSC, with the development of therapeutic approaches specifically targeting its unique pathophysiology. We recommend that further clinical trials are developed specifically for people with HbSC disease, including women, and that where patients with HbSC are included in trials with other types of SCD, these trials should be structured to ensure that enough patients with HbSC are recruited to give meaningful results for outcomes in people with HbSC disease.
Research recommendations
-
1.
More research should be focused on HbSC disease, and therapeutic approaches should be developed specifically targeting its unique pathophysiology (15 agree, 0 disagree, 1 abstention: 100% agreement).
-
2.
Clinical trials should be developed specifically for people with HbSC disease; where patients with HbSC are included in trials with other types of SCD, these trials should be structured to ensure that sufficient numbers of patients with HbSC are recruited to give meaningful results for outcomes in people with HbSC disease (14 agree, 1 disagrees, 1 abstention: 93% agreement).
AUTHOR CONTRIBUTIONS
David C. Rees: Conceptualization; investigation; writing—original draft; methodology; validation; visualization; writing—review and editing; data curation; supervision; resources. Valentine Brousse: Investigation; methodology; validation; visualization; writing—review and editing, supervision. Mariane de Montalembert: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Bart J. Biemond: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Lucia De Franceschi: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Eugene Oteng-Ntim: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Pagona Flevari: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Valeria Pinto: Investigation; methodology; validation; visualization; writing—review and editing; supervision. John James: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Elena Cela: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Stefan Eber: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Rachel Kesse-Adu: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Jennifer Knight-Madden: Investigation; methodology; validation; writing—review and editing; visualization; supervision. France Pirenne: Investigation; methodology; validation; visualization; supervision. Aline Santin: Investigation; methodology; validation; visualization; writing—review and editing; supervision. Andreas Glenthøj: Investigation; writing—original draft; methodology; validation; visualization; writing—review and editing; data curation; supervision; resources.
CONFLICT OF INTEREST STATEMENT
D.C.R: None. V.B: None M.d.M: Boards of Vertex and Theravia, Speakers’ bureau of Novo Nordisk. B.J.B: Research support by: Pfizer, BMS, Novartis, Novo Nordisk; Honoraria for advisory support/lectures/podcast: Pfizer, BMS, Novo Nordisk, Sanofi. L.d.F: None. E.O.N: None. P.F: None. V.P: None J.J: Honoraria: Novartis Ad board, Novo Nordisk, Pfizer; Consultancy: Roche. E.C: None. S.E: None. R.K.A: Speaker honoraria from Vertex, Novo Nordisk, Novartis, and Pfizer. J.M.K.M: None. F.P: None. A.S: None. A.G: Consultancy or advisory board fees: Novo Nordisk, Agios, Pharmacosmos, Vertex Pharmaceuticals, Sanofi; Research support: Novo Nordisk, Sanofi, Agios, Bristol Myers Squibb, AbbVie.
FUNDING
This research received no funding.
ACKNOWLEDGMENTS
We would like to thank Anna Daniel, Lea Lyngø, Olesea Mirza, and Ines Teles Siefers Alves in the EHA Guidelines Department for their support in producing this manuscript and for conducting the online Delphi voting.
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed.
REFERENCES
- 1.Collaborators GBDSCD. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000−2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585‐e599. 10.1016/S2352-3026(23)00118-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Piel FB, Rees DC, DeBaun MR, et al. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol. 2023;10(8):e633‐e686. 10.1016/S2352-3026(23)00096-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010‐2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484. 10.1371/journal.pmed.1001484 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311‐323. 10.1016/S0140-6736(17)30193-9 [DOI] [PubMed] [Google Scholar]
- 5. Nelson M, Noisette L, Pugh N, et al. The clinical spectrum of HbSC sickle cell disease‐not a benign condition. Br J Haematol. 2024;205(2):653‐663. 10.1111/bjh.19523 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC disease. Blood Rev. 2003;17(3):167‐178. 10.1016/s0268-960x(03)00003-1 [DOI] [PubMed] [Google Scholar]
- 7. Rees DC, Thein SL, Osei A, et al. The clinical significance of K‐Cl cotransport activity in red cells of patients with HbSC disease. Haematologica. 2015;100(5):595‐600. 10.3324/haematol.2014.120402 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Di Mauro M, El Hoss S, Nardo‐Marino A, et al. Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea. Am J Hematol. 2023;98(11):E341‐E344. 10.1002/ajh.27074 [DOI] [PubMed] [Google Scholar]
- 9. DeBaun MR, Ghafuri DL, Rodeghier M, et al. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood. 2019;133(6):615‐617. 10.1182/blood-2018-10-880575 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J. 2010;182(18):E839‐E842. 10.1503/cmaj.090449 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Bain BJ, Daniel Y, Henthorn J, et al. Significant haemoglobinopathies: a guideline for screening and diagnosis: a British Society for Haematology Guideline. Br J Haematol. 2023;201(6):1047‐1065. 10.1111/bjh.18794 [DOI] [PubMed] [Google Scholar]
- 12. Gravholt EAE, Petersen J, Mottelson M, et al. The Danish national haemoglobinopathy screening programme: report from 16 years of screening in a low‐prevalence, non‐endemic region. Br J Haematol. 2024;204(1):329‐336. 10.1111/bjh.19103 [DOI] [PubMed] [Google Scholar]
- 13. Marcheco‐Teruel B. Sickle cell anemia in Cuba: prevention and management, 1982‐2018. MEDICC Rev. 2019;21(4):34‐38. 10.37757/MR2019.V21.N4.6 [DOI] [PubMed] [Google Scholar]
- 14. Locock L, Kai J. Parents' experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era. Br J Gen Pract. 2008;58(548):161‐168. 10.3399/bjgp08X277276 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Herington E, Horton J. Genetic carrier screening for cystic fibrosis, Fragile X Syndrome, hemoglobinopathies, and spinal muscular atrophy. CADTH Health Technol Rev. 2021;1(6). https://www.cda-amc.ca/sites/default/files/attachments/2021-07/RC1361 [PubMed] [Google Scholar]
- 16. de Montalembert M, Cappellini MD, Iolascon A, et al. EHA recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies. HemaSphere. 2026;10(6):e70381. 10.1002/hem3.70381 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. de Montalembert M, Cappellini MD, Iolascon A, et al. Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies. HemaSphere. 2026;10(6):e70381. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Bhogal AK, Brunger F. Prenatal genetic counseling in cross‐cultural medicine: a framework for family physicians. Can Fam Physician. 2010;56(10):993‐999. [PMC free article] [PubMed] [Google Scholar]
- 19. Moseley KL, Nasr SZ, Schuette JL, Campbell AD. Who counsels parents of newborns who are carriers of sickle cell anemia or cystic fibrosis? J Genet Couns. 2013;22(2):218‐225. 10.1007/s10897-012-9537-3 [DOI] [PubMed] [Google Scholar]
- 20. Bagnall R, Guy D, Morgan RL, et al. Point‐of‐care diagnostic test accuracy in children and adolescents with sickle cell disease: a systematic review and meta‐analysis. Blood Rev. 2025;69:101243. 10.1016/j.blre.2024.101243 [DOI] [PubMed] [Google Scholar]
- 21. Salomon LJ, Sotiriadis A, Wulff CB, Odibo A, Akolekar R. Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta‐analysis. Ultrasound Obstet Gynecol. 2019;54(4):442‐451. 10.1002/uog.20353 [DOI] [PubMed] [Google Scholar]
- 22. Resta C, Xiong R, Sturrock S, et al. Non‐invasive prenatal testing for the diagnosis of sickle cell disease in high‐risk pregnancies: a systematic review and statistical summary of the current literature. Eur J Obstet Gynecol Reprod Biol. 2026;316:114799. 10.1016/j.ejogrb.2025.114799 [DOI] [PubMed] [Google Scholar]
- 23. Pecker LH, Schaefer BA, Luchtman‐Jones L. Knowledge insufficient: the management of haemoglobin SC disease. Br J Haematol. 2017;176(4):515‐526. 10.1111/bjh.14444 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Segbefia C, Luchtman‐Jones L. Seeing haemoglobin SC: challenging the misperceptions. Br J Haematol. 2024;205(2):404‐405. 10.1111/bjh.19580 [DOI] [PubMed] [Google Scholar]
- 25. Pandya A, Dave K, Desai S, Desai G. Perceptions of patients and stakeholders on a prenatal sickle cell disease screening and its results among tribal populations of Gujarat: a participatory mixed‐method research. J Community Genet. 2025;16(2):167‐181. 10.1007/s12687-025-00768-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Menaa F, Khan BA, Uzair B, Menaa A. Sickle cell retinopathy: improving care with a multidisciplinary approach. J Multidiscip Healthc. 2017;10:335‐346. 10.2147/JMDH.S90630 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Brandsen RP, Diederen RMH, Bakhlakh S, Nur E, Schlingemann RO, Biemond BJ. Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11‐year follow‐up study. Blood Adv. 2023;7(13):3080‐3086. 10.1182/bloodadvances.2022009147 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Leveziel N, Lalloum F, Bastuji‐Garin S, et al. Rétinopathie drépanocytaire: analyse rétrospective portant sur 730 patients suivis dans un centre de référence. J Français d'Ophtalmol. 10.1016/j.jfo.2011.10.007 [DOI] [PubMed] [Google Scholar]
- 29. Lemonne N, Lamarre Y, Romana M, et al. Impaired blood rheology plays a role in the chronic disorders associated with sickle cell‐hemoglobin C disease. Haematologica. 2014;99(5):74‐75. 10.3324/haematol.2014.104745 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Brandsen RP, Diederen RMH, Kocabas G, et al. Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence. Haematologica. 2025;110(5):1092‐1104. 10.3324/haematol.2024.286420 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Lim JI, Okonkwo ON, Ong SS, et al. Anti‐vascular endothelial growth factor therapy for stages 3 and 4 proliferative sickle cell retinopathy results in improved anatomical and visual outcomes. Retina. 2026;46(1):171‐178. 10.1097/IAE.0000000000004658 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829‐838. 10.1182/blood-2015-09-618579 [DOI] [PubMed] [Google Scholar]
- 33. Wang W, Enos L, Gallagher D, et al. Neuropsychologic performance in school‐aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139(3):391‐397. 10.1067/mpd.2001.116935 [DOI] [PubMed] [Google Scholar]
- 34. Guilliams KP, Fields ME, Hulbert ML. Higher‐than‐expected prevalence of silent cerebral infarcts in children with hemoglobin SC disease. Blood. 2015;125(2):416‐417. 10.1182/blood-2014-10-605964 [DOI] [PubMed] [Google Scholar]
- 35. Sathi BK, Yoshida Y, Weaver MR, et al. Unusually high prevalence of stroke and cerebral vasculopathy in hemoglobin SC disease: a retrospective single institution study. Acta Haematol. 2022;145(2):160‐169. 10.1159/000519360 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Brewin JN, Rooks H, Gardner K, et al. Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). Haematologica. 2021;106(6):1770‐1773. 10.3324/haematol.2020.265827 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Ohene‐Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288‐294. [PubMed] [Google Scholar]
- 38. Strouse JJ, Jordan LC, Lanzkron S, Casella JF. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol. 2009;84(9):548‐552. 10.1002/ajh.21476 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Deane CR, Goss D, O'Driscoll S, et al. Transcranial Doppler scanning and the assessment of stroke risk in children with haemoglobin sickle cell disease. Arch Dis Child. 2008;93(2):138‐141. 10.1136/adc.2007.125799 [DOI] [PubMed] [Google Scholar]
- 40. Vieira C, de Oliveira CNC, de Figueiredo LAB, et al. Transcranial Doppler in hemoglobin SC disease. Pediatr Blood Cancer. 2017;64(5):e26342. 10.1002/pbc.26342 [DOI] [PubMed] [Google Scholar]
- 41. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554‐1588. 10.1182/bloodadvances.2019001142 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Willey JZ, Elkind MSV. Do statins improve outcomes after acute ischemic stroke? Nat Rev Neurol. 2011;7(7):364‐365. 10.1038/nrneurol.2011.92 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227‐276. 10.1161/STR.0b013e3181f7d043 [DOI] [PubMed] [Google Scholar]
- 44. Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin sickle cell disease complications: a clinical study of 179 cases. Haematologica. 2012;97(8):1136‐1141. 10.3324/haematol.2011.055202 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Mukisi‐Mukaza M, Manicom O, Alexis C, Bashoun K, Donkerwolcke M, Burny F. Treatment of sickle cell disease's hip necrosis by core decompression: a prospective case‐control study. Orthop Traumatol Surg Res. 2009;95(7):498‐504. 10.1016/j.otsr.2009.07.009 [DOI] [PubMed] [Google Scholar]
- 46. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325(21):1476‐1481. 10.1056/NEJM199111213252104 [DOI] [PubMed] [Google Scholar]
- 47. Lemonne N, Lamarre Y, Romana M, et al. Does increased red blood cell deformability raise the risk for osteonecrosis in sickle cell anemia? Blood. 2013;121(15):3054‐3056. 10.1182/blood-2013-01-480277 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Grimbly C, Escagedo PD, Jaremko JL, et al. Sickle cell bone disease and response to intravenous bisphosphonates in children. Osteoporos Int. 2022;33(11):2397‐2408. 10.1007/s00198-022-06455-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Hernigou P, Trousselier M, Roubineau F, et al. Stem cell therapy for the treatment of hip osteonecrosis: a 30‐year review of progress. Clin Orthop Surg. 2016;8(1):1‐8. 10.4055/cios.2016.8.1.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Mohabey A, De Joseph J, Joseph FK, Deshmukh K, Warjukar P, Gandhi AP. Total hip arthroplasty in sickle cell disease: a systematic review and meta‐analysis of functional outcomes and complications. J Clin Orthop Trauma. 2025;67:103060. 10.1016/j.jcot.2025.103060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med. 1997;102(2):171‐177. 10.1016/s0002-9343(96)00407-x [DOI] [PubMed] [Google Scholar]
- 52. Chawla A, Sprinz PG, Welch J, et al. Weight status of children with sickle cell disease. Pediatrics. 2013;131(4):e1168‐e1173. 10.1542/peds.2012-2225 [DOI] [PubMed] [Google Scholar]
- 53. Hall R, Gardner K, Rees DC, Chakravorty S. High body mass index in children with sickle cell disease: a retrospective single‐centre audit. BMJ Paediatr Open. 2018;2(1):e000302. 10.1136/bmjpo-2018-000302 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886‐895. 10.1056/NEJMoa035477 [DOI] [PubMed] [Google Scholar]
- 55. Guedeney P, Lionnet F, Ceccaldi A, et al. Cardiac manifestations in sickle cell disease varies with patient genotype. Br J Haematol. 2018;181(5):664‐671. 10.1111/bjh.15238 [DOI] [PubMed] [Google Scholar]
- 56. Colella MP, de Paula EV, Machado‐Neto JA, et al. Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica. 2015;100(4):466‐471. 10.3324/haematol.2014.114587 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Naik RP, Streiff MB, Haywood, Jr. C , Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under‐recognized complication. Am J Med. 2013;126(5):443‐449. 10.1016/j.amjmed.2012.12.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123(2):359‐365. 10.1046/j.1365-2141.2003.04594.x [DOI] [PubMed] [Google Scholar]
- 59. Yu TT, Nelson J, Streiff MB, Lanzkron S, Naik RP. Risk factors for venous thromboembolism in adults with hemoglobin SC or Sβ+ thalassemia genotypes. Thromb Res. 2016;141:35‐38. 10.1016/j.thromres.2016.03.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20‐May 21, 2020. Emerging Infect Dis. 2020;26(10):2473‐2476. 10.3201/eid2610.202792 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol. 2011;26(8):1285‐1290. 10.1007/s00467-011-1857-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Drawz P, Ayyappan S, Nouraie M, et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clin J Am Soc Nephrol. 2016;11(2):207‐215. 10.2215/CJN.03940415 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Powars DR, Elliott‐Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med. 1991;115(8):614‐620. 10.7326/0003-4819-115-8-614 [DOI] [PubMed] [Google Scholar]
- 64. Iyer R, Baliga R, Nagel RL, et al. Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea. Am J Hematol. 2000;64(1):47‐52. 10.1002/(sici)1096-8652(200005)64:1<47::aid-ajh8>3.0.co;2-1 [DOI] [PubMed] [Google Scholar]
- 65. Walker TM, Hambleton IR, Serjeant GR. Gallstones in sickle cell disease: observations from The Jamaican Cohort study. J Pediatr. 2000;136(1):80‐85. 10.1016/s0022-3476(00)90054-4 [DOI] [PubMed] [Google Scholar]
- 66. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four‐decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70(3):206‐215. 10.1002/ajh.10140 [DOI] [PubMed] [Google Scholar]
- 67. Lane P, O'Connell J, Lear J, et al. Functional asplenia in hemoglobin SC disease. Blood. 1995;85(8):2238‐2244. [PubMed] [Google Scholar]
- 68. Pourdieu C, El Hoss S, Le Roux E, et al. Relevance of Howell‐Jolly body counts for measuring spleen function in sickle cell disease. Am J Hematol. 2023;98(5):E110‐E112. 10.1002/ajh.26879 [DOI] [PubMed] [Google Scholar]
- 69. Zimmerman SA, Ware RE. Palpable splenomegaly in children with haemoglobin SC disease: haematological and clinical manifestations. Clin Lab Haematol. 2000;22(3):145‐150. 10.1046/j.1365-2257.2000.00304.x [DOI] [PubMed] [Google Scholar]
- 70. Aquino VM, Norvell JM, Buchanan GR. Acute splenic complications in children with sickle cell‐hemoglobin C disease. J Pediatr. 1997;130(6):961‐965. 10.1016/s0022-3476(97)70284-1 [DOI] [PubMed] [Google Scholar]
- 71. Adeyoju AB, Olujohungbe ABK, Morris J, et al. Priapism in sickle‐cell disease; incidence, risk factors and complications—an international multicentre study. BJU Int. 2002;90(9):898‐902. 10.1046/j.1464-410x.2002.03022.x [DOI] [PubMed] [Google Scholar]
- 72. Anele UA, Le BV, Resar LMS, Burnett AL. How I treat priapism. Blood. 2015;125(23):3551‐3558. 10.1182/blood-2014-09-551887 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematology. 2022;2022(1):450‐458. 10.1182/hematology.2022000380 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Salonia A, Eardley I, Giuliano F, et al. European Association of Urology guidelines on priapism. Eur Urol. 2014;65(2):480‐489. 10.1016/j.eururo.2013.11.008 [DOI] [PubMed] [Google Scholar]
- 75. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327‐355. 10.1182/bloodadvances.2019001143 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Murao M, Viana MB. Risk factors for alloimmunization by patients with sickle cell disease. Braz J Med Biol Res. 2005;38(5):675‐682. 10.1590/s0100-879x2005000500004 [DOI] [PubMed] [Google Scholar]
- 77. Zheng Y, Gossett JM, Chen PL, et al. Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease. Blood Adv. 2023;7(17):4799‐4808. 10.1182/bloodadvances.2022008647 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle‐cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773‐2781. 10.1182/blood-2018-02-785964 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol. 1997;98(4):838‐844. 10.1046/j.1365-2141.1997.3173132.x [DOI] [PubMed] [Google Scholar]
- 80. Setayesh T, Chi M, Oestreicher Z, et al. A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea. Blood. 2025;146(1):13‐28. 10.1182/blood.2024028136 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Yawn BP, Buchanan GR, Afenyi‐Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA. 2014;312(10):1033‐1048. 10.1001/jama.2014.10517 [DOI] [PubMed] [Google Scholar]
- 82. Yates AM, Dedeken L, Smeltzer MP, Lebensburger JD, Wang WC, Robitaille N. Hydroxyurea treatment of children with hemoglobin SC disease. Pediatr Blood Cancer. 2013;60(2):323‐325. 10.1002/pbc.24283 [DOI] [PubMed] [Google Scholar]
- 83. Miller MK, Zimmerman SA, Schultz WH, Ware RE. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol. 2001;23(5):306‐308. 10.1097/00043426-200106000-00014 [DOI] [PubMed] [Google Scholar]
- 84. Luchtman‐Jones L, Pressel S, Hilliard L, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016;91(2):238‐242. 10.1002/ajh.24255 [DOI] [PubMed] [Google Scholar]
- 85. Dei‐Adomakoh YA, Segbefia CI, Latham TS, et al. Hydroxyurea for children and adults with hemoglobin SC disease. NEJM Evid. 2025;4(2):EVIDoa2400402. 10.1056/EVIDoa2400402 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Segbefia CI, Smart LR, Stuber SE, et al. Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa. Br J Haematol. 2024;205(6):2470‐2480. 10.1111/bjh.19832 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Traets MJM, Kidane Gembremeskel AS, Eijkelenboom‐Bos J, et al. Iron deficiency in HbSC disease treated with repetitive phlebotomy is associated with fewer sickle cell disease‐related complications. Am J Hematol. 2025;100(11):2123‐2127. 10.1002/ajh.70045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88. Villaboni S, Stuart‐Smith S, De Kreuk A, Rees DC, Brewin JN. Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC. Br J Haematol. 2026; 208(2):683‐690. [DOI] [PubMed] [Google Scholar]
- 89. Lionnet F, Hammoudi N, Stojanovic KS, et al. Iron restriction is an important treatment of hemoglobin SC disease. Am J Hematol. 2016;91(7):320. 10.1002/ajh.24380 [DOI] [PubMed] [Google Scholar]
- 90. Summarell CCG, Sheehan VA. Original research: use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. Exp Biol Med. 2016;241(7):737‐744. 10.1177/1535370216639737 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Iolascon A, Andolfo I, Russo R, et al. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. HemaSphere. 2024;8(7):e108. 10.1002/hem3.108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Villaboni S, Stuart‐Smith S, De Kreuk A, Rees DC, Brewin JN. Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC. Br J Haematol. 2026;208(2):683‐690. 10.1111/bjh.70262 [DOI] [PubMed] [Google Scholar]
- 93. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429‐439. 10.1056/NEJMoa1611770 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l‐glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226‐235. 10.1056/NEJMoa1715971 [DOI] [PubMed] [Google Scholar]
- 95. Nardo‐Marino A, Brousse V, Rees D. Emerging therapies in sickle cell disease. Br J Haematol. 2020;190(2):149‐172. 10.1111/bjh.16504 [DOI] [PubMed] [Google Scholar]
- 96. Nyffenegger N, Zennadi R, Kalleda N, et al. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood. 2022;140(7):769‐781. 10.1182/blood.2021014716 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97. Idowu M, Otieno L, Dumitriu B, et al. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double‐blind, randomised, placebo‐controlled trial. Lancet Haematol. 2025;12(1):e35‐e44. 10.1016/S2352-3026(24)00319-3 [DOI] [PubMed] [Google Scholar]
- 98. Taranath R, Zhao L, Bourne G, et al. Iron restricted erythropoiesis under hepcidin mimetic treatment (PN23114) improved disease parameters in a Mouse Model for sickle cell disease. Blood. 2023;142:1117. 10.1182/blood-2023-182472 [DOI] [Google Scholar]
- 99. Rees DC, Olujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120(5):744‐752. 10.1046/j.1365-2141.2003.04193.x [DOI] [PubMed] [Google Scholar]
- 100. Azul M, Brandow AM. Beyond IV push: alternative methods for management of acute pain in SCD. Hematology. 2024;2024(1):611‐617. 10.1182/hematology.2024000585 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101. Poulter EY, Truszkowski P, Thompson AA, Liem RI. Acute chest syndrome is associated with history of asthma in hemoglobin SC disease. Pediatr Blood Cancer. 2011;57(2):289‐293. 10.1002/pbc.22900 [DOI] [PubMed] [Google Scholar]
- 102. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855‐1865. 10.1056/NEJM200006223422502 [DOI] [PubMed] [Google Scholar]
- 103. George A, Conneely SE, Mangum R, Fasipe T, Lupo PJ, Scheurer ME. Splenic complications in pediatric sickle cell disease: a retrospective cohort review. Pediatr Blood Cancer. 2024;71(10):e31219. 10.1002/pbc.31219 [DOI] [PubMed] [Google Scholar]
- 104. Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166(2):165‐176. 10.1111/bjh.12950 [DOI] [PubMed] [Google Scholar]
- 105. Elenga N, Celicourt D, Muanza B, et al. Dengue in hospitalized children with sickle cell disease: a retrospective cohort study in the French departments of America. J Infect Public Health. 2020;13(2):186‐192. 10.1016/j.jiph.2019.07.015 [DOI] [PubMed] [Google Scholar]
- 106. Rankine‐Mullings A, Reid ME, Moo Sang M, Richards‐Dawson MA, Knight‐Madden JM. A retrospective analysis of the significance of haemoglobin SS and SC in disease outcome in patients with sickle cell disease and dengue fever. EBioMedicine. 2015;2(8):937‐941. 10.1016/j.ebiom.2015.07.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107. Gendreau S, Coupry LM, Cappy P, et al. Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units. Blood Adv. 2025;9(22):5695‐5707. 10.1182/bloodadvances.2025015947 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108. Tsitsikas DA, Gallinella G, Patel S, Seligman H, Greaves P, Amos RJ. Bone marrow necrosis and fat embolism syndrome in sickle cell disease: increased susceptibility of patients with non‐SS genotypes and a possible association with human parvovirus B19 infection. Blood Rev. 2014;28(1):23‐30. 10.1016/j.blre.2013.12.002 [DOI] [PubMed] [Google Scholar]
- 109. Brousse V, Holvoet L, Pescarmona R, et al. Low incidence of COVID‐19 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon‐1 activation? Haematologica. 2021;106(10):2746‐2748. 10.3324/haematol.2021.278573 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110. Youner ER, Haupt TL, El‐Shatanofy M, et al. An analysis of risk factors for sensorineural hearing loss in children with sickle cell disease. Otol Neurotol. 2026;47(1):57‐63. 10.1097/MAO.0000000000004674 [DOI] [PubMed] [Google Scholar]
- 111. Obadina MA, Pecker LH. Proactive management to improve outcomes of high‐risk pregnancy in people with sickle cell disease. Hematology. 2025;2025(1):511‐522. 10.1182/hematology.2025000744 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112. Gibson SMP, Hunter TA, Charles PE, et al. Current obstetric outcomes in Jamaican women with sickle hemoglobinopathy—a balance of risks for aspirin? J Perinat Med. 2024;52(5):485‐493. 10.1515/jpm-2023-0378 [DOI] [PubMed] [Google Scholar]
- 113. Oteng‐Ntim E, Pavord S, Howard R, et al. Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline. Br J Haematol. 2021;194(6):980‐995. 10.1111/bjh.17671 [DOI] [PubMed] [Google Scholar]
- 114. Baronciani D, Boumendil A, Dalissier A, et al. Hematopoietic stem cell transplantation in thalassemia and sickle cell disease: report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000−2017. Blood. 2018;132(1):168. [Google Scholar]
- 115. de la Fuente J, Galimard J, Dalissier A, et al. Allogeneic transplantation for sickle cell disease offers high rates of cure with low incidence of severe chronic GVHD in both children and adults: real world data from 2010‐2021. An analysis of the European Society for Blood and Bone Marrow Transplantation Haemoglobinopathy Registry. Blood. 2024;144(1):176. [Google Scholar]
- 116. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA‐identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548‐1556. 10.1182/blood-2016-10-745711 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117. Rostami T, Rad S, Rostami MR, et al. Hematopoietic stem cell transplantation in sickle cell disease: a multidimentional review. Cell Transplant. 2024;33:9636897241246351. 10.1177/09636897241246351 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem‐cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309‐2317. 10.1056/NEJMoa0904971 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119. de Franceschi L, Locatelli F, Rees D, et al. Selecting patients with sickle cell disease for gene addition or gene editing‐based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference. HemaSphere. 2025;9(3):e70089. 10.1002/hem3.70089 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120. Wilks A, Steinberg MH, Frangoul H. Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion. Blood. 2025;146(20):2385‐2391. 10.1182/blood.2025029964 [DOI] [PubMed] [Google Scholar]
- 121. Zhai J, Papizan JB, Yao Y, et al. A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies. Blood Adv. 2025;9(23):6220‐6233. 10.1182/bloodadvances.2025016793 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed.
